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Background: There has been great variation and uncertainty about how many and what CFTR mutations to include in cystic fibrosis (CF) newborn
screening algorithms, and very little research on this topic using large populations of newborns.
Methods: We reviewed Wisconsin screening results for 1994–2008 to identify an ideal panel.
Results: Upon analyzing approximately 1 million screening results, we found it optimal to use a 23 CFTR mutation panel as a second tier when an
immunoreactive trypsinogen (IRT)/DNA algorithm was applied for CF screening. This panel in association with a 96th percentile IRT cutoff gave
a sensitivity of 97.3%, but restricting the DNA tier to F508del was associated with 90% (Pb .0001).
Conclusions: Although CFTR panel selection has been challenging, our data show that a 23 mutation method optimizes sensitivity and is
advantageous. The IRT cutoff value, however, is actually more critical than DNA in determining CF newborn screening sensitivity.
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in 1979 after Crossley et al [1] demonstrated the elevation of
immunoreactive trypsinogen (IRT) in the blood of infants
eventually diagnosed with CF. This led to regional programs
using IRT/IRT screening [2,3]. However, due to concerns
regarding suboptimal screening sensitivity of the initial high
IRT cutoff and observations that the second specimens of some
CF patients showed precipitous decreases in IRT [4], the
IRT/DNA-F508del method [5–7] was developed to incorporate
a lower IRT cutoff and a strategy applying the discovery of the⁎ Corresponding author at: University of Wisconsin School of Medicine and
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doi:10.1016/j.jcf.2011.02.001cystic fibrosis transmembrane conductance regulator (CFTR)
gene [8]. While many studies have shown that CF NBS is
beneficial [9], only limited work has been done to evaluate the
long term effectiveness of the screening tests. Yet during 2010,
many newborns in Europe and most babies in North America
and Australasia are being screened with an IRT/DNA algorithm
that now often employs CFTR multi-mutation analyses [10,11].
However, the number of mutations in the screening panel and
the methods used for mutation detection vary greatly with some
regions still testing only for F508del [11] and others for as many
as 400 mutations [12] or performing expanded genetic analysis
by gene scanning and selective sequencing.
Although there has been a trend in recent years to add more
CFTR mutations for screening [13], published guidance is
currently available from only two sources: 1) the revised carrier
screening recommendations of American College of Medicald by Elsevier B.V. All rights reserved.
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suggestion in the “European best practice guidelines for cystic
fibrosis neonatal screening” published from a consensus
conference [15] with qualifications: “A second tier NBS panel
should be designed in order to include well known CF-causing
mutations represented in the local CF population, including
those alleles frequently occurring in ethnic minorities.” The
important issue of how many CFTR mutations in IRT/DNA
screening remains unresolved due in part to a lack of published
data. Thus, we evaluated DNA results from screening almost 1
million newborns during 1994 to 2008 in Wisconsin.
1. Methods
Wisconsin has used an IRT/DNA screening algorithm in a CF
routine NBS program since July 1994 when the randomization
phase of our randomized clinical trial was completed [16]. IRT
was measured throughout the 14.5 years of this study with
DELFIA kits manufactured by PerkinElmer (Wallac Oy, Finland).
CFTR mutations were identified as F508del alone in screening
period 1 (July, 1994–February, 2002) or by CFTR multiple
mutation analysis in period 2 (March, 2002–December,2008)
using the Roche Diagnostic Corp (Indianapolis, IN) linear array
kit , or Hologic, Inc. (Madison, WI) Invader chemistry. Both
assays detect the 23mutations currently recommended byACMG
after revision of their original 25 mutation panel recommendation
[14].
Infantswith positive screening (i.e., IRT≥96th percentile and1
or 2 CFTRmutations detected) are referred for a sweat test in a CF
center. When a child with CF is diagnosed based on signs and
symptoms after a negative IRT/DNA screen, the CF center reports
the case via our ongoing surveillance program [16,17], and the case
is recorded as a screening false negative. This study population
consists of the CF screening positive cases with a confirmed CF
diagnosis and screening false negatives born between July, 1994
and December, 2008. This study was approved by the University
of Wisconsin-Madison Institutional Review Board.
2. Results
During the 14.5 years, a total of 986,997 infants were
screened. In this population, 234 screening positives wereTable 1
CF Screening false negatives and the cause of delayed diagnosis after IRT/DNA an
Year Mutation 1 Mutation 2 IRTa Age at diagn
1995 p. R553X Unknown 53 (56) 4 months old
1996 p. R553X p. R1161X 64 (56) 6 weeks old
1997 p. R347P Unknown 82 (56) 7 weeks old
2000 3007delG Unknown 99 (64) 9 months old
2001 Unknown Unknown 44 (66) 7 years old
2002 p. G551D p. Q1291Hc 53 (64) 4 years old
2003 F508del F508del 45 (51) 1 year old
2004 p. R170Hc Unknown 13 (62) 3 years old
aIRT was reported as ng/mL. The value reported in the parenthesis was the IRT cutoff
for IRT to a floating cutoff calculated on a daily basis as described elsewhere [17].
bNote that all sweat chloride values were diagnostic of CF [20] and that 6 of the 8 p
cCFTR mutation associated with pancreatic sufficiency, while all other alleles list arconfirmed with CF including 127 in period 1, and 107 in
period 2. In 187 CF confirmed cases with two identified CFTR
mutations (79.9%), 91 cases had F508del/F508del (38.9%), 87
cases had F508del and another mutant allele (37.1%), and 9
cases had other/other alleles (3.8%). In 46 CF confirmed cases
with one identified CFTR mutation, 42 patients had F508del,
and 4 cases had a different CFTR mutation. One CF confirmed
patient is receiving care in a different state, and CFTR mutation
information is not available. In 6 non-Caucasian cases (three
African American, two Native American and one Hispanic),
five had at least one F508del allele, and one was compound
heterozygote of G542X/1812-1 GNA. There were 8 screening
false negative cases, including 5 in period 1, and 3 in period 2.
The CFTR mutation distributions and causes of false negatives,
which are mainly due to low IRT levels, are listed in Table 1.
Note that most of the CFTR mutations are associated with
pancreatic insufficiency and that 6 of the 8 false negatives
occurred after 2 months of age.
The frequencies of CFTR alleles included in ACMG 23
mutation panel in 107 CF cases identified in period 2 are listed
in Table 2, which are similar to the predicted alleles from a
previous study involving 360 CF patients receiving care in
Wisconsin [6]. Note that 12 of the 23 mutations in the revised
ACMG list were detected but that some (e.g., 3849+10KbCNT)
did not add to the cumulative detection rate. The significant
association of IRT elevations and CF risk in newborns with one
CFTR mutant allele detected using ACMG 23 mutation panel is
demonstrated in Table 3, which extends previous observations
[6,18]. These data provide an indication of the value of the 96th
percentile IRT cutoff value; in fact, 13 of 45 (29%) patients
diagnosed with a single mutant allele had IRT levels below the
99th percentile, which is commonly used in Europe [10].
3. Discussion
The demographics of Wisconsin for live births are as follows:
74.4% white, 10.0% black, 9.8% Hispanic/Latino, 4.1% Asian
American, and 1.6% American Indian (http://dhs.wisconsin.gov/
births/pdf/08births.pdf), which resembles theU.S. demographics as
a whole (quickfacts.census.gov/qfd/states/00000.html). After
screening ~1 million newborns in Wisconsin over 14 years, we
calculated a CF prevalence in Wisconsin of 1 in 4079 or 1 in 3112alyses.
osis Sweat test results (mmol/L)b Cause of false negative
94 IRT below the cut-off
109 F508del alone as the 2nd tier
108 F508del alone as the 2nd tier
110 Rare mutations
59 IRT below the cut-off
77 IRT below the cut-off
121 IRT below the cut-off
66 IRT below the cut-off
value for that testing date. In 1999, Wisconsin changed from a fixed cutoff value
atients were identified after 2 months of age.
e associated with pancreatic insufficiency.
Table 2
CFTR mutations from ACMG 23 mutation panel in 107 CF patients identified
via newborn screening program.
CFTR mutation a Proportion
of allele
Frequency
of allele (%)
Cumulative
detection (%) b
F508del 137/214 64.02 92.52
3849+10KbCNT 6/214 2.80 92.52 c
G542X 5/214 2.34 94.39
N1303K 4/214 1.87 98.13
R117H 4/214 1.87 99.07
R553X 3/214 1.40 99.07
1717-1GNA 2/214 0.93 99.07
G551D 1/214 0.47 100
R347P 1/214 0.47 100
A455E 1/214 0.47 100
W1282X 1/214 0.47 100
621+1GNT 1/214 0.47 100
a The other 11 mutations in ACMG 23 mutation panel are G85E, 711+1GNT,
R334W, I507del, R560T, 1898+1GNA, 2184delA, 2789+5GNA, 3120+1GNA,
R1162X and 3659delC.
b The identification of either one or two mutant alleles prompts further
confirmatory evaluations, so some mutant alleles do not contribute to the detection
rate when they are in compound heterozygote.
c Note that 3849+10KbCNT did not contribute to the cumulative detection rate
because all 6 of the patients with this allele also had a F508del mutation.
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screening positives with confirmed CF and 8 actual screening false
negatives, the calculated overall sensitivity of the screening
program is 96.7% (96.2% in period 1, and 97.3% in period 2).
Notably, during period 1, when F508del was the only CFTR
mutation used in the second tier screening, 3 of 5 false negative
cases had IRT levels above the cutoff including two cases with at
least one mutation listed in 23 CFTRmutation panel. Furthermore,
if F508del alone also had been used as the second tier test in
period 2, we could have missed an additional 8 cases, resulting in
90.0% screening sensitivity rather than the observed 97.3%
(Pb .0001 by McNemar's test). This demonstrates that the 23
CFTR mutation panel significantly improves CF screening
sensitivity. In addition, identifying two mutant alleles by 1 week
of age in ~80% of patients eventually diagnosed with CF provides
several advantages such as expediting and facilitating follow-up
and interpretation of intermediate sweat chloride test results [20].
On the other hand, increasing the number of mutations from
F508del only to the 23 allele panel led to an average of 67 more
sweat tests per year (146/year vs 213/year, which is ~1 per week
more sweat tests and is a readily manageable increase). Thus, we
have concluded that the 23 alleles recommended by the ACMG
gives us both optimal, though imperfect, screening sensitivity and
efficiency without causing excessive work or expense.Table 3
Correlation of IRT Level and CF risk in newborns with one mutant allele detected
IRT level
(ng/mL)
IRT percentile No. CF/no.
infants
CF risk, %
exact 95%
b99 96.0–98.9th 13/1029 1.3 (0.7,
100–124 99.0–99.3th 9/147 6.1 (2.8,
125–149 99.4–99.7th 8/48 16.7 (7.5,
≥150 99.8–100th 15/31 48.4 (30.2It is also obvious from the data presented in Table 1 that the
IRT cutoff value is most significant in determining CF
screening sensitivity because 5 out of 8 false negative cases, 2
from period 1 and 3 from period 2, had IRT levels below the
DNA reflex cutoff. Interestingly, all but one had IRT values
close to the cutoff. Thus, it remains a challenge to set a proper
IRT cutoff to maximize CF screening sensitivity without
generating more screening false positives.
Our DNA data demonstrate that it is satisfactory to use a 23
CFTR mutation panel as the second tier when an IRT/DNA
algorithm is applied to the current Wisconsin population for CF
newborn screening. With this panel, only two patients had
alleles that were not detected, less than 1% of the diagnosed
cases in this study. Interestingly, the frequency of alleles closely
aligns with our predictions [6] in 1997 when we began to
evaluate transforming our DNA tier from F508del only to a
CFTR multi-mutation analysis. As we reported originally [6]
with fewer observations, the IRT levels provide valuable
information to assess CF risk in infants with one CFTR
mutation detected. The relative risk of having CF increases
significantly when IRT level is greater than 100 ng/mL and
approaches 50% with IRT≥150 ng/mL (N99.8th percentile).
This relationship can also help CF centers plan follow-up
evaluations and management.
The frequency of CF-causing alleles reported herein
(Table 2) is similar to U.S. data available from the CF
Foundation (www.cff.org/UploadedFiles/research; http://www.
cftr2.org/index1.php). This suggests that our conclusions are
generally applicable to the nation as a whole, although at least
one state (California) with a large proportion of Hispanic-Latino
births might need other alleles in the CFTR panel. In addition,
because the frequency of the major mutations in Canada is
similar [21], we believe that the ACMG-23 panel would be
applicable to almost all of North America. Moreover, the
methods and much of the data reported herein may be
applicable to Western European countries. Certainly, all CF
newborn screening programs worldwide need to decide on the
optimal number of CFTR mutations, and the quantitative
distribution of the major alleles is similar in typical European
populations and their derivatives such as Euro-Americans, as
described previously [21]. Nevertheless, an important issue in
decisions regarding CFTRmutation panels relates to the clinical
consequences of mutant alleles, as has been pointed out for
R117H [22]. Although our data are insufficient to reach a
conclusion about this international policy issue, it should be
emphasized that missed cases often have pancreatic insuffi-
ciency, as we found, and that even children with pancreaticusing the ACMG CFTR 23 mutation panel.
(binomial
CI)
Relative risk, (95% CI)
compared with IRT b99
P-value compared
with IRT b99
2.2)
11.3) 4.8 (2.1, 11.1) b0.0001
30.2) 13.2 (5.7, 30.3) b0.0001
, 66.9) 38.3 (20.0, 73.4) b0.0001
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depletion [23]. Consequently, this challenging topic must be
addressed with more long term clinical data and a formal policy
development process.
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